Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide

Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide
Trade Name
Orphan Indication Acute myeloid leukemia
USA Market Approval USA
USA Designation Date 2014-05-14 00:00:00
Sponsor Karyopharm Therapeutics, Inc.;2 Mercer Road;Natick, Massachusetts, 01760
Related Access Program
Children’s Hospital Los Angeles – Acute myeloid leukemia Jazz Pharmaceuticals – Secondary AML Celator Pharmaceuticals – Secondary AML University of California, San Francisco – Acute myeloid leukemia Emory University – Acute myeloid leukemia